Q-omics provides the consensus-scored PLCD3 profile across patient tissues and cancer cell-line models. PLCD3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PLCD3 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, PLCD3 protein abundance shows 20,085 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, THCA, and GBM as cancer lineages where PLCD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLCD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLCD3 survival associations across molecular data types. PLCD3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLCD3 RNA expression–survival associations across cancer types. High PLCD3 expression shows unfavorable associations in LUAD, KICH, PAAD and ACC, but favorable associations in BLCA and BRCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PLCD3 RNA expression.
This table summarizes PLCD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PLCD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLCD3 shows lower tumor expression in COAD, KICH and BLCA and higher tumor expression in THCA, KIRP and LIHC. The THCA box plot shows higher PLCD3 RNA expression in tumor versus normal tissue (log2 FC = +3.287, t-test p < 0.001).
This table shows molecular features associated with PLCD3 in patient tissues and cancer cell lines. In patient samples, PLCD3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLCD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
